Encorafenib - Array BioPharma

Drug Profile

Encorafenib - Array BioPharma

Alternative Names: Encorafenib; LGX-818; NVP-LGX818; NVP-LGX818-NXA; ONO-7702

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Novartis Pharmaceuticals Corporation
  • Developer Array BioPharma; German Cancer Research Center; Merck KGaA; Novartis Pharmaceuticals Corporation; University of Heidelberg
  • Class Antineoplastics; Carbamates; Pyrazoles; Pyrimidines; Small molecules; Sulfonamides
  • Mechanism of Action Proto oncogene protein b raf inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Malignant melanoma
  • Phase III Colorectal cancer
  • Phase II Multiple myeloma; Solid tumours

Most Recent Events

  • 06 Feb 2018 Preregistration for Malignant melanoma (Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease) in Switzerland, Australia (PO)
  • 06 Feb 2018 Analysis of overall survival from the phase III COLUMBUS trial in Malignant melanoma released by Array BioPharma and Pierre Fabre
  • 20 Jan 2018 Interim safety, efficacy and pharmacodynamics data from the phase III BEACON CRC trial in Colorectal cancer released by Array BioPharma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top